RHODE ISLAND HOSPITAL

N876TLXYGCG4

1HTV4

2025-11-04

http://www.rhodeislandhospital.org/

LIFESPAN

LIFESPAN

2024-11-05

2000-07-20

1HTV4

Active

Non-Manufacturer

2024-11-05

2029-11-05

2025-11-04

MARY GASBARRO

http://www.rhodeislandhospital.org/

1245607795

2023-04-05

View on NPI website

MR. PETER K MARKELL

CFO

4014447914

261QM1300X - Multi-Specialty Clinic/Center

Yes

+1 401-444-6779

4014446912

+1 401-721-5706

4017933846

UCC-1 Standard

202431423470

2024-12-13

Assignment

RHODE ISLAND HOSPITAL

Debtor(s)

Omnicell, Inc.

Secured Parties

UCC-3 CONTINUATION

202431360090

2024-11-25

Continuation

THE MIRIAM HOSPITAL

Debtor(s)

EMMA PENDLETON BRADLEY HOSPITAL

Debtor(s)

LIFESPAN CORPORATION

Debtor(s)

RHODE ISLAND HOSPITAL

Debtor(s)

UCC-3 CONTINUATION

202431103020

2024-10-03

Continuation

RHODE ISLAND HOSPITAL

Debtor(s)

Omnicell, Inc.

Secured Parties

CREEKRIDGE CAPITAL

Secured Parties

36C24125N0149

View Award on USAspending website

AWARD

BPA CALL

$50,000

$50,000

$50,000

Department of Veterans Affairs

2024-12-01

AFFILIATE - MUSCLE & NERVE BIOPSIES AND DERMATOPATHOLOGY CONSULTATIONS FOR VISN1

621511: MEDICAL LABORATORIES

6550: IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS

36C24124N0145

View Award on USAspending website

AWARD

BPA CALL

$52,000

$52,000

$52,000

Department of Veterans Affairs

2023-12-01

AFFILIATE - MUSCLE & NERVE BIOPSIES AND DERMATOPATHOLOGY CONSULTATIONS FOR VISN1

621511: MEDICAL LABORATORIES

Q301: MEDICAL- LABORATORY TESTING

36C24123P0657

View Award on USAspending website

AWARD

PURCHASE ORDER

$0

$0

$0

Department of Veterans Affairs

2023-05-01

ROLE OF M1 LEG AREA VOLITIONAL AND STEREOTYPED CONTROL OF THE LOWER LIMB (CLINICAL STUDY), FOR PROVIDENCE VAMC.

541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

AN42: HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH

NONPROFIT WITH 501C3 IRS STATUS (OTHER THAN AN INSTITUTION OF HIGHER EDUCATION)

2025-04-17

View on USAspending

Department of Health and Human Services

A SLEEP HYGIENE INTERVENTION TO IMPROVE SLEEP HEALTH IN URBAN, LATINO MIDDLE SCHOOL CHILDREN - PROJECT SUMMARY/ABSTRACT: SLEEP IS ESSENTIAL FOR OPTIMAL HEALTH AND DEVELOPMENT. POOR SLEEP IS ASSOCIATED WITH IMPAIRED FUNCTIONING AND ACADEMIC PERFORMANCE, AND WORSE HEALTH OUTCOMES IN CHILDREN. LATINO CHILDREN ARE DISPROPORTIONATELY PRESENT IN URBAN SETTINGS, AND DUE TO THEIR EXPOSURE TO HIGHER LEVELS OF URBAN AND CULTURAL STRESSORS, ARE AT GREATER RISK FOR POOR SLEEP HYGIENE AND QUALITY. OVER THE PAST 3 YEARS, WE HAVE DEMONSTRATED THE ACCEPTABILITY, FEASIBILITY AND PRELIMINARY EFFICACY OF A NOVEL SLEEP HYGIENE INTERVENTION, SIESTA (SCHOOL INTERVENTION TO ENHANCE LATINO STUDENTS’ TIME ASLEEP) FOR IMPROVING SLEEP HYGIENE AND SLEEP DURATION IN URBAN LATINO MIDDLE SCHOOLERS IN TWO GEOGRAPHIC AREAS WITH A HIGH PROPORTION OF URBAN LATINO CHILDREN AT INCREASED RISK FOR POOR SLEEP HEALTH: PROVIDENCE, RHODE ISLAND, AND SAN JUAN, PUERTO RICO. SIESTA INVOLVES 4 GROUP SESSIONS ADMINISTERED IN SCHOOL TO LATINO MIDDLE SCHOOLERS (6TH-8TH GRADE) AND TWO CHILD-CAREGIVER SESSIONS ADMINISTERED REMOTELY BY A BILINGUAL (ENGLISH/SPANISH) TRAINED FACILITATOR FROM THE COMMUNITY. THE GOAL OF THIS APPLICATION IS TO ADMINISTER A TWO-SITE HYBRID TYPE 1 EFFECTIVENESS-IMPLEMENTATION DESIGN TO EVALUATE SIESTA’S EFFECTS ON A LARGER-SCALE- FOR ADDRESSING LATINO MIDDLE SCHOOLER’S SLEEP HEALTH, WHILE ALSO ASSESSING IMPLEMENTATION DETERMINANTS. THE FIRST AIM OF THE PROPOSED WORK IS TO EVALUATE SIESTA THROUGH A LARGE-SCALE RCT WITH URBAN MIDDLE SCHOOL STUDENTS IN PROVIDENCE, RI AND SAN JUAN, PUERTO RICO. WE WILL ENROLL 150 LATINO CHILDREN PER SITE (N=300), AND RANDOMLY ASSIGN THEM EITHER TO THE SIESTA INTERVENTION, OR TO THE SLEEP EDUCATION PLUS CHILD HEALTH ATTENTION-CONTROL CONDITION (9 GROUPS OF EACH OF THE TWO CONDITIONS, PER SITE; 8-9 STUDENTS PER GROUP). WE WILL EVALUATE TREATMENT EFFECTS ON PRIMARY SLEEP OUTCOMES SUCH AS SLEEP DURATION, EFFICIENCY AND SLEEP ONSET LATENCY AND ON SECONDARY SLEEP OUTCOMES INVOLVING SLEEP HYGIENE BEHAVIORS, THE SLEEP ENVIRONMENT AND SLEEP-RELATED DISTURBANCES AND IMPAIRMENT. ASSESSMENTS WILL OCCUR PRIOR TO, IMMEDIATELY FOLLOWING, AND AT 4, 8, AND 12 MONTHS AFTER THE INTERVENTION. OVER 1 YEAR, WE EXPECT SIESTA PARTICIPANTS WILL HAVE IMPROVED SLEEP OUTCOMES, SLEEP HYGIENE BEHAVIORS AND LESS SLEEP-RELATED IMPAIRMENT THAN CONTROLS. THE SECOND AIM IS TO IDENTIFY IMPLEMENTATION DETERMINANTS AND PRELIMINARY IMPLEMENTATION OUTCOMES OF SIESTA TO PREPARE FOR FUTURE LARGE-SCALE IMPLEMENTATION IN OTHER URBAN SCHOOL SETTINGS. WE WILL CONDUCT A MIXED METHODS PROCESS EVALUATION WITH INPUT FROM COMMUNITY PARTNERS USING THE RE-AIM FRAMEWORK THROUGHOUT AND FOLLOWING ADMINISTRATION OF THE RCT. THE PROPOSED WORK BUILDS ON A 20-YEAR COLLABORATION BETWEEN OUR RESEARCH TEAMS IN RI AND PR, AND AN INVESTMENT IN ADVANCING KNOWLEDGE OF MULTI-LEVEL FACTORS AFFECTING PEDIATRIC HEALTH DISPARITIES IN CHILDREN THROUGH EVIDENCE-BASED, SUSTAINABLE INTERVENTIONS. SIESTA HAS THE POTENTIAL TO IMPROVE SLEEP OUTCOMES IN URBAN LATINO CHILDREN AND THEIR DAYTIME FUNCTIONING, AND TO ADDRESS A CRITICAL GAP OF THE NEED FOR TAILORED AND EFFECTIVE SLEEP HYGIENE INTERVENTIONS FOR CHILDREN AT GREATER RISK FOR POOR SLEEP HEALTH.

$1,365,467

$0

$0

NONPROFIT WITH 501C3 IRS STATUS (OTHER THAN AN INSTITUTION OF HIGHER EDUCATION)

2025-04-18

View on USAspending

Department of Health and Human Services

GENE THERAPY FOR LONG QT SYNDROME TYPE 2 - ABSTRACT THERE ARE >500 PATHOLOGIC VARIANTS WITHIN 17 GENES CAUSING CONGENITAL LONG QT SYNDROME, WHICH LEADS TO POLYMORPHIC VENTRICULAR TACHYCARDIA (PVT) AND SUDDEN CARDIAC DEATH (SCD). ABOUT 30% OF THE MUTATIONS ARE CONCENTRATED IN THE KCNH2 GENE RESULTING IN LOSS-OF-FUNCTION OF THE RAPIDLY ACTIVATING DELAYED RECTIFIER POTASSIUM CURRENT IKR CAUSING PROLONGATION OF THE ACTION POTENTIAL DURATION AND QT INTERVAL (LQT2). WE DEVELOPED A TRANSGENIC RABBIT MODEL FOR LQT2 THAT RECAPITULATE THE HUMAN PHENOTYPE. THIS APPLICATION IS AIMED AT DEVELOPING GENE THERAPY FOR LQT2 USING OUR RABBIT MODEL AND AN AAV9-MEDIATED MOSAIC GENE EXPRESSION OF HERG. AIM 1 TO RESCUE THE PHENOTYPE OF LQT2G BY DELIVERING AAV9-ENCODED SHRNA THAT WILL ABOLISH EXPRESSION OF BOTH THE HUMAN PORE MUTANT TRANSGENE AND ENDOGENOUS RERG WITH AN SHRNA-RESISTANT HERG (HERG*) UNDER THE CONTROL OF THE CMV PROMOTER AT DOSES OF 6E13VG/KG AND 2E14VG/KG AS COMPARED TO VEHICLE CONTROL. THE AIM ALSO PROPOSES TO STUDY THE CELLULAR PHENOTYPE OF THE TREATED RABBITS AS COMPARED TO VEHICLE CONTROL. AIM 2 PROPOSES TO MONITOR ANT TEST THE TWO GROUPS FOR SPONTANEOUS AND INDUCIBLE ARRHYTHMIAS. THIS APPLICATION OUTLINES THE ROADMAP FOR GENE THERAPY OF ALL VARIANTS CAUSING HUMAN LQT2 SYNDROME AND HAS THE POTENTIAL TO REVOLUTIONIZE THE THERAPY OF THIS SYNDROME.

$1,541,400

$0

$0

NONPROFIT WITH 501C3 IRS STATUS (OTHER THAN AN INSTITUTION OF HIGHER EDUCATION)

2025-05-08

View on USAspending

Department of Health and Human Services

CAMKII AND ENDOTHELIAL SK CHANNEL FUNCTION IN DIABETIC CORONARY MICROCIRCULATION - ENDOTHELIAL DYSFUNCTION PLAYS A KEY ROLE IN THE PATHOGENESIS OF DIABETIC (DM) MICROVASCULAR DISEASE, INCREASING MORBIDITY AND MORTALITY. DYSFUNCTION OF SMALL CONDUCTANCE CALCIUM-ACTIVATED-POTASSIUM (SK) CHANNELS CONTRIBUTES STRONGLY TO DM-INDUCED ENDOTHELIAL DYSFUNCTION IN THE CORONARY MICROCIRCULATION. EMERGING EVIDENCE HAS DEMONSTRATED THAT DM CAUSES EXCESSIVE PHOSPHORYLATION OF CAMKII (P-CAMKII), O-GLCNACYLATION OF CAMKII (OG- CAMKII), AND/OR OXIDATION OF CAMKII (OX-CAMKII), ALONG WITH ENHANCED MITOCHONDRIAL ROS (MROS) PRODUCTION IN THE HEART AND ENDOTHELIAL CELLS (EC). HOWEVER, THE ROLE OF CAMKII POSTTRANSLATIONAL MODIFICATIONS IN DM DYSREGULATION OF ENDOTHELIAL SK CHANNELS AND CORONARY MICROVASCULAR FUNCTION REMAINS LARGELY UNDEFINED. OF NOTE, WE RECENTLY FOUND THAT CHRONIC ACTIVATION/OXIDATION OF CAMKII AND O-GLCNACYLATION DURING DM REDUCED ENDOTHELIAL SK CHANNEL ACTIVITY AND CORONARY MICROVASCULAR RELAXATION, SUGGESTING THAT CAMKII PLAYS A KEY ROLE IN DM DYSREGULATION OF ENDOTHELIAL SK CHANNELS. THUS, THE OVERALL GOAL OF THIS PROJECT IS TO INVESTIGATE HOW CAMKII POSTTRANSLATIONAL MODIFICATIONS DURING CHRONIC DM ALTERS ENDOTHELIAL SK CHANNEL ACTIVITY AND CORONARY MICROVASCULAR ENDOTHELIAL FUNCTION. OUR CENTRAL HYPOTHESIS IS THAT SUSTAINED/EXCESSIVE P-CAMKII, OG-CAMKII, AND OX-CAMKII DURING CHRONIC DM DYSREGULATES ENDOTHELIAL SK CHANNEL ACTIVITY AND ENDOTHELIAL FUNCTION, RESULTING IN CORONARY MICROVASCULAR DYSFUNCTION. WE WILL TEST OUR HYPOTHESIS BY COMPLETING 4 SPECIFIC AIMS: TO INVESTIGATE THE MOLECULAR MECHANISMS BY WHICH DM-INDUCED PERSISTENT P-CAMKII (AIM 1), OG-CAMKII (AIM 2) AND OX-CAMKII (AIM 3) ALL LEAD TO SK CHANNEL AND CORONARY ENDOTHELIAL DYSFUNCTION, AND TO EXPLORE IF INHIBITION/BLOCKADE OF DIABETIC POSTTRANSLATIONAL MODIFICATIONS OF CAMKII IMPROVES CORONARY MICROVASCULAR RELAXATION (AIM 4). AIM 1 WILL STUDY THE EFFECTS OF INHIBITING P-CAMKII USING A TRANSGENIC MOUSE MODEL OF ENDOTHELIAL CELLS EXPRESSING SYNTHETIC CAMKII INHIBITORY PEPTIDE (AC3-I) OR CAMKII INHIBITORS, ON ENDOTHELIAL SK CHANNEL ACTIVITY IN THE SETTING OF T1DM/T2DM; AND ALSO EXAMINE THE EFFECTS OF SK-CHANNEL MUTATION BY USING SITE-DIRECTED MUTAGENESIS ON CAMKII PHOSPHORYLATION SITES COMBINED WITH LC/MS-MS. AIM 2 WILL TEST WHETHER GENETIC MUTATION (CAMKIIΔ S280 KNOCK-IN) OR PHARMACOLOGIC INHIBITION OF OG-CAMKII WITH SPECIFIC O-GLCNAC INHIBITORS AFFECTS ENDOTHELIAL SK CURRENT DENSITY, OG-CAMKII, AND OG-CAMKII-SK INTERACTIONS IN T1DM AND/OR T2DM MICE. AIM 3 WILL EXAMINE INHIBITION OF OX- CAMKII USING A KNOCK-IN MOUSE MODEL OF OXIDATION-RESISTANT CAMKII (MM-VV) AND SK-ACTIVATOR-INDUCED RELAXATION IN THE PRESENCE OF DM; AND FURTHER DETERMINE WHETHER CHRONIC INHIBITION OF MROS AFFECTS ENDOTHELIAL SK CURRENT DENSITY, OX-CAMKII, P-CAMKII AND OG-CAMKII IN DM MICE. AIM 4 WILL INVESTIGATE THE EFFECTS OF INHIBITION/BLOCKADE OF CAMKII POSTTRANSLATIONAL MODIFICATION DURING DM ON CORONARY MICROVASCULAR RELAXATION. THIS PROPOSAL WILL IMPROVE OUR UNDERSTANDING OF DM HEART/VESSEL DISEASE BY STUDYING NOVEL MECHANISMS BY WHICH CAMKII DYSREGULATION AFFECTS ENDOTHELIAL SK CHANNEL FUNCTION. SUCH WORK WILL LEAD TO NOVEL APPROACHES FOR IMPROVING CORONARY MICROVASCULAR FUNCTION IN DM PATIENTS WITH CORONARY HEART DISEASE.

$533,302

$0

$0

NONPROFIT WITH 501C3 IRS STATUS (OTHER THAN AN INSTITUTION OF HIGHER EDUCATION)

2025-04-09

View on USAspending

Department of Health and Human Services

IMPROVING SOCIAL CONNECTEDNESS THROUGH DIGITAL HEALTH TO ENHANCE RECOVERY FROM OUD AMONG THE JUSTICE INVOLVED POPULATION. - ABSTRACT INDIVIDUALS WITH CRIMINAL JUSTICE INVOLVEMENT EXPERIENCE ELEVATED RATES OF OPIOID USE DISORDER (OUD) AND ARE AT SIGNIFICANTLY HIGHER RISK OF DEATH FROM OPIOID OVERDOSE IN THE FIRST YEAR FOLLOWING RELEASE FROM JAIL/PRISON. MEDICATIONS FOR OUD (MOUD) ARE AN EVIDENCE-BASED APPROACH TO TREATING OUD AND OFFER EXTENSIVE BENEFITS INCLUDING LOWERING RATES OF MORTALITY, ILLICIT OPIOID USE, HIV TRANSMISSION, VIOLENT CRIME, AND ARREST. WHILE MANY CORRECTIONAL SETTINGS HAVE STARTED TO IMPLEMENT MOUD, THERE ARE SIGNIFICANT CHALLENGES TO CONTINUING MEDICATION/TREATMENT WHILE TRANSITIONING BACK TO THE COMMUNITY. INTERSECTIONAL STIGMA RELATED TO ADDICTION AND HISTORY OF INCARCERATION IS ASSOCIATED WITH GREATER DIFFICULTIES WITH REINTEGRATION, INCREASED ISOLATION, AND HEIGHTENED FEELINGS OF LONELINESS. LACK OF SOCIAL CONNECTEDNESS FURTHER SERVES AS A RISK FACTOR FOR DECREASED RETENTION IN TREATMENT, DISCONTINUATION OF MOUD, AND A RETURN TO SUBSTANCE USE. PEER SUPPORT IS A KEY COMPONENT OF MANY EVIDENCE-BASED OUD RECOVERY PROGRAMS. WHEN USED IN CONJUNCTION WITH MOUD, IT HAS THE POTENTIAL TO IMPROVE PERCEIVED SOCIAL SUPPORT, SELF-EFFICACY, AND TREATMENT ENGAGEMENT. HOWEVER, ACCESS TO LIVE PEER SUPPORT HAS BEEN CHALLENGED BY COVID RESTRICTIONS, HIGHLIGHTING A CRITICAL NEED FOR DIGITAL HEALTH PLATFORMS TO DELIVER PEER SUPPORT. THE MARIGOLD MOBILE PEER SUPPORT (“MPS”) APP IS A DEDICATED, SECURE, MOBILE APPLICATION THAT EMPLOYS STRUCTURED, LIVE PEER MODERATION TO GUIDE TEXT-BASED CONVERSATIONS WITH GROUPS OF PARTICIPANTS AND BEHIND-THE-SCENES NATURAL LANGUAGE PROCESSING (NLP) TO AUTOMATICALLY IDENTIFY “RED FLAG” CONTENT WITHIN PEER CHATS. WHILE INITIAL WORK DEMONSTRATES THE UTILITY OF DEPLOYING THE MPS APP IN OUTPATIENT TREATMENT SETTINGS FOR OUD, IT HAS YET TO BE TESTED IN CORRECTIONAL SETTINGS OR AMONG JUSTICE-INVOLVED POPULATIONS. THE GOAL OF THE PROPOSED APPLICATION IS TO ADVANCE EVIDENCE-BASED AND SCALABLE TREATMENTS FOR OUD, BY DECREASING LONELINESS AND ENHANCING PERCEIVED SOCIAL SUPPORT VIA NOVEL APPLICATION OF AN ESTABLISHED MOBILE APP AMONG INDIVIDUALS WITH A HISTORY OF ENGAGING IN MOUD WHILE IN JAIL/PRISON. THE STUDY WILL BE ACCOMPLISHED THROUGH TWO PRIMARY AIMS: (1) DEVELOP AN IMPLEMENTATION MANUAL TO GUIDE DELIVERY OF THE MPS APP FOR THOSE WITH A RECENT (PAST YEAR) HISTORY OF ENGAGING IN MOUD WHILE IN JAIL/PRISON BY CONDUCTING IN-DEPTH INTERVIEWS WITH PROSPECTIVE APP USERS AND OTHER KEY STAKEHOLDERS; AND (2) CONDUCT A RANDOMIZED CONTROLLED TRIAL TO ASSESS FEASIBILITY, ACCEPTABILITY, AND PRELIMINARY EFFICACY OF THE MPS APP RELATIVE TO ENHANCED TREATMENT- AS-USUAL AMONG INDIVIDUALS WITH A RECENT (PAST YEAR) HISTORY OF ENGAGING IN MOUD WHILE IN JAIL/PRISON. FINDINGS FROM THIS STUDY WILL BE USED TO DEVELOP A R01 APPLICATION TO CONDUCT A FULLY-POWERED HYBRID TYPE 1 EFFECTIVENESS-IMPLEMENTATION STUDY.

$752,553

$0

$0

NONPROFIT WITH 501C3 IRS STATUS (OTHER THAN AN INSTITUTION OF HIGHER EDUCATION)

2025-05-06

View on USAspending

Department of Health and Human Services

VALIDATION OF THE YUCATAN MINIPIG AS A PRECLINICAL MODEL FOR WRIST BONE ARTHROPLASTY - ABSTRACT THE GOAL OF THIS PROPOSAL IS TO ESTABLISH THE YUCATAN MINIPIG AS A PRECLINICAL ANIMAL MODEL FOR INNOVATIVE THERAPEUTICS AND ARTHROPLASTIES DESIGNED TO TREAT CARPAL BONE PATHOLOGIES ASSOCIATED WITH LIGAMENT INJURIES AND SEVERE OSTEOARTHRITIS (OA). DEGENERATIVE AND TRAUMATIC WRIST PAIN IS COMMON, OFTEN RESULTING IN ACTIVITY RESTRICTIONS AND THE INABILITY TO WORK. ULTIMATELY, WRIST REPLACEMENT IS THE ONLY TREATMENT CAPABLE OF RETAINING WRIST FUNCTION WHILE COUNTERACTING THE DEGENERATIVE CHANGES. HOWEVER, OUTCOMES AFTER WRIST ARTHROPLASTY TREATMENT ARE MUCH POORER THAN THOSE FOR THE HIP, KNEE, OR SHOULDER. TREATMENTS FOR WRIST OSTEOARTHRITIS HAVE EVOLVED MUCH MORE SLOWLY THAN THESE LARGER JOINTS, DUE IN LARGE PART TO THE LACK OF STUDY AND AVAILABLE DATA. THE WRIST’S COMPLEXITY ALSO PRESENTS A SIGNIFICANT CHALLENGE, COMPOUNDED BY THE LACK OF A VALIDATED PRECLINICAL ANIMAL MODEL THAT CAN BE USED TO INTERROGATE THE CONSEQUENCES OF CARPAL INSTABILITY AND EVALUATE THE ABILITY OF CARPAL BONE REPLACEMENTS TO RESTORE CARPAL FUNCTION AND LIMIT OSTEOARTHRITIS PROGRESSION. PRECLINICAL LARGE ANIMAL MODELS HAVE BEEN CRUCIAL FOR THE DEVELOPMENT, TRANSLATION, AND FDA APPROVAL OF ARTHROPLASTY DEVICES FOR HIPS, KNEES, AND SPINES. WITH AN AGING AND INCREASINGLY ACTIVE OLDER POPULATION, THE NEED FOR IMPROVED TREATMENTS FOR DEGENERATIVE WRIST PATHOLOGIES IS GROWING RAPIDLY. ACCORDINGLY, THE GOAL OF THIS PROPOSAL IS TO ESTABLISH THE YUCATAN MINIPIG AS A MODEL FOR CARPAL BONE THERAPEUTICS AND ARTHROPLASTIES THAT ARE DESIGNED TO TREAT SEVERE OSTEOARTHRITIS. THIS GOAL WILL BE ACHIEVED IN TWO INDEPENDENT AIMS. IN THE FIRST, WE WILL QUANTIFY THE BIOMECHANICS OF THE MINIPIG CARPUS AND THE KINEMATICS OF THE RADIAL CARPAL BONE (RCB) USING ESTABLISHED IN VITRO BIOMECHANICAL TESTING. IN THE SECOND, WE WILL EVALUATE OA PROGRESSION IN VIVO, AFTER INDUCED CARPAL INSTABILITY AND AFTER TREATMENT WITH A CARPAL BONE HEMIARTHROPLASTY. IN BOTH AIMS THREE CARPAL CONDITIONS WILL BE EVALUATED, WITH THE INTACT CARPUS AS A REFERENCE: DIVISION OF THE RADIAL INTERMEDIATE LIGAMENT (RIL GROUP), DIVISION OF THE RIL+DORSAL INTERCARPAL LIGAMENT (RIL+DIC GROUP), AND HEMIARTHROPLASTY OF THE RADIAL CARPAL BONE (RCBH GROUP). OUTCOME MEASURES FOR AIM 1 WILL INCLUDE WRIST BIOMECHANICS AND RADIAL CARPAL BONE KINEMATICS. OUTCOME MEASURES FOR AIM 2 WILL INCLUDE SPATIOTEMPORAL MEASUREMENTS OF GAIT AND CARTILAGE HEALTH. AT THE CONCLUSION OF THIS R21 PROJECT, WE WILL, FOR THE FIRST TIME, HAVE FULLY CHARACTERIZED THE BIOMECHANICS OF THE PORCINE CARPUS AND WE WILL HAVE ESTABLISHED A NOVEL ANIMAL MODEL FOR CARPAL BONE HEMIARTHROPLASTY AND INNOVATIVE THERAPEUTICS. THIS PROJECT WILL ADVANCE THE TREATMENT OF CARPAL INSTABILITIES BY PROVIDING A FIT-FOR-PURPOSE ANIMAL MODEL CAPABLE OF EVALUATING IMPORTANT FEATURES OF INNOVATIVE TREATMENTS AND ARTHROPLASTY DESIGNS (E.G., SHAPE, MATERIAL, FINISH, BEARING SURFACES, FIXATION METHODS, BONE/SOFT TISSUE INGROWTH, AND WEAR DEBRIS), AS WELL AS THE BROAD RANGE OF FUTURE INNOVATIVE THERAPEUTICS, SUCH AS TISSUE ENGINEERED LIGAMENTS, CARTILAGE AND OSTEOCHONDRAL GRAFTS, AND PATIENT-SPECIFIC 3D PRINTED IMPLANTS.

$390,386

$0

$0

2024-01-08

Complaint

100 WILLARD AVE., PROVIDENCE, RI, 02905

Safety

Partial

2023-09-11

Referral

593 EDDY STREET, PROVIDENCE, RI, 02903

Health

Partial

2020-08-03

Referral

593 EDDY STREET, PROVIDENCE, RI, 02903

Health

Partial

2016-08-11

Complaint

593 EDDY STREET, PROVIDENCE, RI, 02903

Safety

Partial

2014-08-04

Complaint

593 EDDY STREET, PROVIDENCE, RI, 02903

Health

Partial

05-0258954

Government Instrumentality, Title-Holding Corporation, Charitable Organization, Agricultural Organization, Board of Trade, Pleasure, Recreational, or Social Club, Fraternal Beneficiary Society, Order or Association, Voluntary Employees' Beneficiary Association (Non-Govt. Emps.), Domestic Fraternal Societies and Associations, Teachers Retirement Fund Assoc., Benevolent Life Insurance Assoc., Burial Association, Credit Union, Mutual Insurance Company or Assoc. Other Than Life or Marine, Corp. Financing Crop Operations, Supplemental Unemployment Compensation Trust or Plan, Employee Funded Pension Trust (Created Before 6/25/59), Post or Organization of War Veterans, Legal Service Organization, Black Lung Trust, Multiemployer Pension Plan, Veterans Assoc. Formed Prior to 1880, Trust Described in Sect. 4049 of ERISA, Title Holding Co. for Pensions, etc., State-Sponsored High Risk Health Insurance Organizations, State-Sponsored Workers' Compensation Reinsurance, ACA 1322 Qualified Nonprofit Health Insurance Issuers, Apostolic and Religious Org. (501(d)), Cooperative Hospital Service Organization (501(e)), Cooperative Service Organization of Operating Educational Organization (501(f)), Child Care Organization (501(k)), Charitable Risk Pool, Qualified State-Sponsored Tuition Program, 4947(a)(1) - Private Foundation (Form 990PF Filer)

1993-11

Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)

2024-08-26

Pending

Missing

Both plaintiff and defendant demand jury

Civil Rights Employment

MICHE

Plaintiff

RHODE ISLAND HOSPITAL

Defendant

2023-09-19

Terminated

no monetary award

Plaintiff demands jury

Medical Malpractice

MARCHETTI, INDIVIDUALLY,

Plaintiff

RHODE ISLAND HOSPITAL

Defendant

2023-01-12

Terminated

no monetary award

Neither plaintiff nor defendant demands jury

Labor Management Relations Act

UNITED NURSES & ALLIED PROFESS

Plaintiff

RHODE ISLAND HOSPITAL

Defendant